Skip to main content

Advertisement

SpringerLink
Log in

Chemotherapy in Ewing’s sarcoma

  • Review Article
  • Published:
Indian Journal of Orthopaedics Aims and scope Submit manuscript

Abstract

Ewing’s sarcoma constitutes three per cent of all pediatric malignancies. Ewing’s sarcoma has generally been more responsive to chemotherapy than adult-type sarcomas, and chemotherapy is now recommended for all patients with this disease. It is essential to integrate local control measures in the form of surgery and/or radiotherapy at the appropriate time, along with chemotherapy to eradicate the disease. This approach has improved the survival substantially to the tune of 70% in localized disease, although outcome for metastatic disease remains dismal. Newer therapeutic approaches are required to improve outcome for metastatic and recurrent or refractory Ewing’s sarcoma in organized co-operative group trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Rodríguez-Galindo C, Liu T, Krasin MJ, Wu J, Billups CA, Daw NC, et al. Analysis of prognostic factors in ewing sarcoma family of tumors: review of St. Jude Children’s Research Hospital studies. Cancer 2007;110:375–84.

    Article  PubMed  Google Scholar 

  2. Cotterill SJ, Ahrens S, Paulussen M, Jürgens HF, Voûte PA, Gadner H, et al. Prognostic factors in Ewing’s tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing’s Sarcoma Study Group. J Clin Oncol 2000;18:3108–14.

    Article  CAS  PubMed  Google Scholar 

  3. Greene FL, Page DL, Fleming ID, A. Fritz, CM. Balch, D.G. Haller et al., eds. AJCC Cancer Staging Manual. 6th ed. New York, NY: Springer; 2002.

    Book  Google Scholar 

  4. Ladenstein R, Pötschger U, Le Deley M, Whelan J, Paulussen M, Oberlin O, et al. A prognostic score at diagnosis for Ewing tumor patients with metastatic disease at extrapulmonary sites. J Clin Oncol 2009;27:10544

    Google Scholar 

  5. Juergens H, Manner D, Gerss J, Ranfit A, Paulussen M, Dirksen U. TNM staging in Ewing sarcomas. Pediatr Blood Cancer 2009;5:759.

    Google Scholar 

  6. Bacci G, Longhi A, Ferrari S, Mercuri M, Versari M, Bertoni F. Prognostic factors in non-metastatic Ewing’s sarcoma tumor of bone: an analysis of 579 patients treated at a single institution with adjuvant or neoadjuvant chemotherapy between 1972 and 1998. Acta Oncol 2006;45:469–75.

    Article  PubMed  Google Scholar 

  7. Paulussen M, Ahrens S, Burdach S, Craft A, Dockhorn-Dworniczak B, Dunst J, et al. Primary metastatic (stage IV) Ewing tumor: survival analysis of 171 patients from the EICESS studies. European Intergroup Cooperative Ewing Sarcoma Studies. Ann Oncol 1998;9:275–81.

    Article  CAS  PubMed  Google Scholar 

  8. Wunder JS, Paulian G, Huvos AG, Heller G, Meyers PA, Healey JH. The histological response to chemotherapy as a predictor of the oncological outcome of operative treatment of Ewing sarcoma. J Bone Joint Surg Am 1998;80:1020–33.

    Article  CAS  PubMed  Google Scholar 

  9. Oberlin O, Deley MC, Bui BN, Gentet JC, Philip T, Terrier P, et al. Prognostic factors in localized Ewing’s tumours and peripheral neuroectodermal tumours: the third study of the French Society ofPaediatric Oncology (EW88 study). Br J Cancer 2001;85:1646–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Ewing’s J. Further report of endothelial myeloma of bone. Proc N Y Pathol Soc 1924;24:93–54.

    Google Scholar 

  11. Jenkin RD. Ewing’s sarcoma a study of treatment methods. Clin Radiol 1966;17:97–106.

    Article  CAS  PubMed  Google Scholar 

  12. Sutow WW, Sullivan MP. Cyclophosphamide therapy in children with Ewing’s sarcoma. Cancer Chemother Rep 1962;23:55–4.

    CAS  PubMed  Google Scholar 

  13. Pinkel D. Cyclophosphamide in children with cancer. Cancer 1962;15:42–60.

    Article  CAS  PubMed  Google Scholar 

  14. Hustu HO, Holton C, James D Jr, Pinkel D. Treatment of Ewing’s sarcoma with concurrent radiotherapy and chemotherapy. J Pediatr 1968;73:249–51.

    Article  CAS  PubMed  Google Scholar 

  15. Rosen G, Wollner N, Tan C, Wu SJ, Hajdu SI, Cham W, et al. Proceedings: Disease-free survival in children with Ewing’s sarcoma treated with radiation therapy and adjuvant four-drug sequential chemotherapy. Cancer 1974;33:384–93.

    Article  CAS  PubMed  Google Scholar 

  16. Nesbit ME Jr, Gehan EA, Burgert EO Jr, Vietti TJ, Cangir A, Tefft M, et al. Multimodal therapy for the management of primary, nonmetastatic Ewing’s sarcoma of bone: a long-term follow-up of the First Intergroup study. J Clin Oncol 1990;8:1664–74.

    Article  PubMed  Google Scholar 

  17. Burgert EO Jr, Nesbit ME, Garnsey LA, Gehan EA, Herrmann J, Vietti TJ, et al. Multimodal therapy for the management of nonpelvic, localized Ewing’s sarcoma of bone: intergroup study IESS-II. J Clin Oncol 1990;8:1514–24.

    Article  PubMed  Google Scholar 

  18. Hayes FA, Thompson EI, Meyer WH, Kun L, Parham D, Rao B, et al. Therapy for localized Ewing’s sarcoma of bone. J Clin Oncol 1989;7:208–13.

    Article  CAS  PubMed  Google Scholar 

  19. Donaldson SS, Torrey M, Link MP, Glicksman A, Gilula L, Laurie F, et al. A multidisciplinary study investigating radiotherapy in Ewing’s sarcoma: end results of POG #8346. Pediatric Oncology Group. Int J Radiat Oncol Biol Phys 1998;42:125–35.

    Article  CAS  PubMed  Google Scholar 

  20. Jürgens H, Exner U, Gadner H, Harms D, Michaelis J, Sauer R, et al. Multidisciplinary treatment of primary Ewing’s sarcoma of bone. A 6-year experience of a European Cooperative Trial. Cancer 1988;61:23–32.

    Article  PubMed  Google Scholar 

  21. Craft AW, Cotterill SJ, Bullimore JA, Pearson D. Long-term results from the first UKCCSG Ewing’s Tumour Study (ET-1). United Kingdom Children’s Cancer Study Group (UKCCSG) and the Medical Research Council Bone Sarcoma Working Party. Eur J Cancer 1997;33:1061–9.

    Article  CAS  PubMed  Google Scholar 

  22. Craft A, Cotterill S, Malcolm A, Spooner D, Grimer R, Souhami R, et al. Ifosfamide-containing chemotherapy in Ewing’s sarcoma: The Second United Kingdom Children’s Cancer Study Group and the Medical Research Council Ewing’s Tumor Study. J Clin Oncol 1998;16:3628–33.

    Article  CAS  PubMed  Google Scholar 

  23. Grier HE, Krailo MD, Tarbell NJ, Link MP, Fryer CJ, Pritchard DJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing’s sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 2003; 348:694–701.

    Article  CAS  PubMed  Google Scholar 

  24. Womer RB, Daller RT, Fenton JG, Miser JS. Granulocyte colony stimulating factor permits dose intensification by interval compression in the treatment of Ewing’s sarcomas and soft tissue sarcomas in children. Eur J Cancer 2000;36:87–94.

    Article  CAS  PubMed  Google Scholar 

  25. Granowetter L, Womer R, Devidas M, Perlman E, Shamberger R, Link M, et al. Comparison of dose intensified and standard dose chemotherapy for the treatment of non-metastatic Ewing’s sarcoma and primitive neuroectodermal tumor of bone and soft tissue: a Pediatric Oncology Group-Children’s Cancer Group phase III trial. Med Pediatr Oncol 2001;37:172.

    Google Scholar 

  26. Granowetter L, Womer R, Devidas M, Krailo M, Wang C, Bernstein M, et al. Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children’s Oncology Group Study. J Clin Oncol 2009;27:2536–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Womer RB, West DC, Krailo MD, Dickman PS, Pawel B. Randomized comparison of every-two-week v. every-three-week chemotherapy in Ewing sarcoma family tumors (ESFT). J Clin Oncol 2008;26:10504.

    Article  Google Scholar 

  28. Kushner BH, Meyers PA, Gerald WL, Healey JH, La Quaglia MP, Boland P, et al. Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing’s sarcoma, in children and young adults. J Clin Oncol 1995;13:2796–804.

    Article  CAS  PubMed  Google Scholar 

  29. Kolb EA, Kushner BH, Gorlick R, Laverdiere C, Healey JH, LaQuaglia MP, et al. Long-term event-free survival after intensive chemotherapy for Ewing’s family of tumors in children and young adults. J Clin Oncol 2003;21:3423–30.

    Article  CAS  PubMed  Google Scholar 

  30. Meyer WH, Kun L, Marina N, Roberson P, Parham D, Rao B, et al. Ifosfamide plus etoposide in newly diagnosed Ewing’s sarcoma ofbone. J Clin Oncol 1992;10:1737–42.

    Article  CAS  PubMed  Google Scholar 

  31. Marina NM, Pappo AS, Parham DM, Cain AM, Rao BN, Poquette CA, et al. Chemotherapy dose-intensification for pediatric patients with Ewing’s family of tumors and desmoplastic small round-cell tumors: a feasibility study at St. Jude Children’s Research Hospital. J Clin Oncol 1999;17:180–90.

    Article  CAS  PubMed  Google Scholar 

  32. Paulussen M, Ahrens S, Dunst J, Winkelmann W, Exner GU, Kotz R, et al. Localized Ewing tumor of bone: final results of the cooperative Ewing’s Sarcoma Study CESS 86. J Clin Oncol 2001;19:1818–29.

    Article  CAS  PubMed  Google Scholar 

  33. Juergens C, Weston C, Lewis I, Whelan J, Paulussen M, Oberlin O, et al. Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial. Pediatr Blood Cancer 2006;47:22–9.

    Article  PubMed  Google Scholar 

  34. Meyers PA, Krailo MD, Ladanyi M, Chan KW, Sailer SL, Dickman PS, et al. High-dose melphalan, etoposide, total-body irradiation, and autologous stem-cell reconstitution as consolidation therapy for high-risk Ewing’s sarcoma does not improve prognosis. J Clin Oncol 2001;19:2812–20.

    Article  CAS  PubMed  Google Scholar 

  35. Schiffman KS, Bensinger WI, Appelbaum FR, Rowley S, Lilleby K, Clift RA, et al. Phase II study of high-dose busulfan, melphalan and thiotepa with autologous peripheral blood stem cell support in patients with malignant disease. Bone Marrow Transplant 1996;17:943–50.

    CAS  PubMed  Google Scholar 

  36. Kushner BH, Meyers PA. How effective is dose-intensive/ myeloablative therapy against Ewing’s sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan-Kettering experience and a literature review. J Clin Oncol 2001;19:870–80.

    Article  CAS  PubMed  Google Scholar 

  37. Burdach S, van Kaick B, Laws HJ, Ahrens S, Haase R, Körholz D, et al. Allogeneic and autologous stem-cell transplantation in advanced Ewing tumors. An update after long-term follow-up from two centers of the European Intergroup study EICESS. Stem-Cell Transplant Programs at Düsseldorf University Medical Center, Germany and St. Anna Kinderspital, Vienna, Austria. Ann Oncol 2000;11:1451–62.

    Article  CAS  PubMed  Google Scholar 

  38. Schuck A, Ahrens S, Paulussen M, Kuhlen M, Könemann S, Rübe C, et al. Local therapy in localized Ewing tumors: results of 1058 patients treated in the CESS 81, CESS 86, and EICESS 92 trials. Int J Radiat Oncol Biol Phys 2003;55:168–77.

    Article  PubMed  Google Scholar 

  39. Elomaa I, Blomqvist CP, Saeter G, Akerman M, Stenwig E, Wiebe T, et al. Five-year results in Ewing’s sarcoma. The Scandinavian Sarcoma Group experience with the SSG IX protocol. Eur J Cancer 2000;36:875–80.

    Article  CAS  PubMed  Google Scholar 

  40. Bramer JA, Abudu AA, Grimer RJ, Carter SR, Tillman RM. Do pathological fractures influence survival and local recurrence rate in bony sarcomas? Eur J Cancer 2007;43:1944–51.

    Article  CAS  PubMed  Google Scholar 

  41. Paulussen M, Ahrens S, Craft AW, Dunst J, Fröhlich B, et al. Ewing’s tumors with primary lung metastases: survival analysis of 114 (European Intergroup) Cooperative Ewing’s Sarcoma Studies patients. J Clin Oncol 1998;16:3044–52.

    Article  CAS  PubMed  Google Scholar 

  42. Whelan JS, Burcombe RJ, Janinis J, Baldelli AM, Cassoni AM. A systematic review of the role of pulmonary irradiation in the management of primary bone tumours. Ann Oncol 2002;13:23–30.

    Article  CAS  PubMed  Google Scholar 

  43. Leavey PJ, Mascarenhas L, Marina N, Chen Z, Krailo M, Miser J, et al. Prognostic factors for patients with Ewing sarcoma (EWS) at first recurrence following multi-modality therapy: A report from the Children’s Oncology Group. Pediatr Blood Cancer 2008;51:334–8.

    Article  PubMed  PubMed Central  Google Scholar 

  44. McTiernan AM, Cassoni AM, Driver D, Michelagnoli MP, Kilby AM, Whelan JS. Improving Outcomes After Relapse in Ewing’s Sarcoma: Analysis of 114 Patients From a Single Institution. Sarcoma 2006;2006:1–8.

    Google Scholar 

  45. Saylors RL 3rd, Stine KC, Sullivan J, Kepner JL, Wall DA, Bernstein ML, et al. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. J Clin Oncol 2001;19:3463–9.

    Article  CAS  PubMed  Google Scholar 

  46. Bernstein M, Goorin AM, Devidas M, Lafreniere D, Stine K, Meyers P et al. Topotecan and topotecan/cyclophosphamide window therapy in patients with Ewing’s sarcoma metastatic at diagnosis: an intergroup Pediatric Oncology Group study (P-9457). Med. Pediatr. Oncol 2001;37:176.

    Google Scholar 

  47. Wagner LM, Crews KR, Iacono LC, Houghton PJ, Fuller CE, McCarville MB, et al. Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors. Clin Cancer Res 2004;10:840–8.

    Article  CAS  PubMed  Google Scholar 

  48. Casey DA, Wexler LH, Merchant MS, Chou AJ, Merola PR, Price AP, et al. Irinotecan and temozolomide for Ewing sarcoma: the Memorial Sloan-Kettering experience. Pediatr Blood Cancer 2009;53:1029–34.

    Article  PubMed  Google Scholar 

  49. Wagner LM, McAllister N, Goldsby RE, Rausen AR, McNall-Knapp RY, McCarville MB, et al. T Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma. Pediatr Blood Cancer 2007;48:132–9.

    Article  PubMed  Google Scholar 

  50. Maki RG, Wathen JK, Patel SR, Priebat DA, Okuno SH, Samuels B, et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002. J Clin Oncol 2007;25:2755–63.

    Article  CAS  PubMed  Google Scholar 

  51. Paulussen M, Ahrens S, Lehnert M, Taeger D, Hense HW, Wagner A, et al. Second malignancies after ewing tumor treatment in 690 patients from a cooperative German/Austrian/ Dutch study. Ann Oncol 2001;12:1619–30.

    Article  CAS  PubMed  Google Scholar 

  52. Steinherz LJ, Steinherz PG, Tan CT, Heller G, Murphy ML. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 1991;266:1672–7.

    Article  CAS  PubMed  Google Scholar 

  53. Wexler LH, Andrich MP, Venzon D, Berg SL, Weaver-McClure L, Chen CC, et al. Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. J Clin Oncol 1996;14:362–72.

    Article  CAS  PubMed  Google Scholar 

  54. Bernstein M, Kovar H, Paulussen M, Randall RL, Schuck A, Teot LA, et al. Ewing’s sarcoma family of tumors: current management. Oncologist. 2006;11(5):503–19.

    Article  CAS  PubMed  Google Scholar 

  55. Kovar H, Aryee DN, Jug G, Henöckl C, Schemper M, Delattre O, et al. In vitro EWS/FLI-1 antagonists induce growth inhibition of Ewing tumor cells. Cell Growth Differ 1996;7:429–37.

    CAS  PubMed  Google Scholar 

  56. Lambert G, Bertrand JR, Fattal E, Subra F, Pinto-Alphandary H, Malvy C, et al. EWS fli-l antisense nanocapsules inhibits ewing sarcoma-related tumor in mice. Biochem Biophys Res Commun. 2000;279(2):401–6.

    Article  CAS  PubMed  Google Scholar 

  57. Scotlandi K, Maini C, Manara MC, Benini S, Serra M, Cerisano V, et al. Effectiveness of insulin-like growth factor I receptor antisense strategy against Ewing’s sarcoma cells. Cancer Gene Ther 2002;9(3):296–307.

    Article  CAS  PubMed  Google Scholar 

  58. Scotlandi K, Benini S, Nanni P, Lollini P-L, Nicoletti G, Landuzzi L, et al. Blockage of insulin-like growth factor-I receptor inhibits the growth of Ewing’s sarcoma in athymic mice. Cancer Res 1998;58:4127–31.

    CAS  PubMed  Google Scholar 

  59. Scotlandi K, Baldini N, Cerisano V, Manara MC, Benini S, Serra M, et al. CD99 engagement: an effective therapeutic strategy for Ewing tumors. Cancer Res 2000;60:5134–42.

    CAS  PubMed  Google Scholar 

  60. Ludwig J. Ewing sarcoma: historical perspectives, current state-of-the-art, and opportunities for targeted therapy in the future. Current Opinion in Oncology 2008;20:412–18.

    Article  PubMed  Google Scholar 

  61. Houghton PJ, Morton CL, Kolb EA, Gorlick R, Lock R, Carol H, et al. Initial testing (stage 1) of the mTOR inhibitor rapamycin by the pediatric preclinical testing program. Pediatr Blood Cancer 2008;50:799–805.

    Article  PubMed  Google Scholar 

  62. Iyer RS, Rao SR, Gurjal A, Nair CN, Pai SK, Kurkure PA, et al. Ewing’s sarcoma. J Surg Oncol 1993;52:188–92.

    Article  CAS  PubMed  Google Scholar 

  63. Advani SH, Rao DN, Dinshaw KA, Nair CN, Gopal R, Vyas JJ, et al. Adjuvant chemotherapy in Ewing’s sarcoma. J Surg Oncol 1986;32:76–8.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatric Hematology and Oncology, Rajiv Gandhi Cancer Institute and Research Centre, Sector 5, Rohini, Delhi, 110085, India

    Sandeep Jain &  Gauri Kapoor (Senior Consultant and Head)

Authors
  1. Sandeep Jain
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gauri Kapoor
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gauri Kapoor.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jain, S., Kapoor, G. Chemotherapy in Ewing’s sarcoma. IJOO 44, 369–377 (2010). https://doi.org/10.4103/0019-5413.69305

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.4103/0019-5413.69305

Key words

Search

Navigation